-
公开(公告)号：KR100296250B1
公开(公告)日：2001-10-25
申请号：KR1019980012818
申请日：1998-04-10
Applicant: 한국과학기술연구원
IPC: A61K36/725 , A61K36/752 , A61P3/06 , A61P9/12
Abstract: PURPOSE: A composition containing a jujube extract and a tangerine pericarp extract containing naringin and hesperidin is provided which has an effect on prevention of adult diseases and cancer such as liver diseases, hypertension, arteriosclerosis, hyperlipidemia or the like when administered to animals. CONSTITUTION: This composition comprises a jujube extract and hesperidin, hesperetin, naringin, naringenin or a mixture thereof as flavonoid originated from a tangerine pericarp extract in a weight ratio of 1:0.001 to 1:0.1. For an example, 5kg jujube is extracted with 15L water at 100deg.C for 2hr two times, followed by filtering. The filtrate is then concentrated under reduced pressure to produce 2kg extract. And 500g tangerine is extracted with 5L ethanol at 60deg.C for 5 hr to produce 190g extract. The jujube extract and tangerine pericarp extract can be orally or parenterally administered at a dose of 0.1 to 5g, preferably 0.5 to 1g and 0.1 to 10g, preferably 0.5 to 2g/kg.weight.day respectively.
-
2.发明公开네오헤스페리딘디하이드로칼콘을포함하는동맥경화증,고지혈증,간질환,고혈당증의예방및치료용조성물 失效包含NEOHESPERIDIN DIHYDROCHALCONE的组合物，用于预防和治疗高脂血症，肠梗塞，肝病和高血压
公开(公告)号：KR1020000019720A
公开(公告)日：2000-04-15
申请号：KR1019980037963
申请日：1998-09-15
Applicant: 한국과학기술연구원
Abstract: PURPOSE: A pharmaceutical composition and functional food and drink comprising neohesperid in dihydrochalcone are provided, for treating and preventing hyper lipidemia, arteriosclerosis, a liver disease and hyperglycemia. CONSTITUTION: The pharmaceutical composition comprises neohesperid in dihydrochalcone ineffective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of neohesperid in dihydrochalcone. Neohesperidin dihydrochalcone reduces the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase) and a lipid in blood, inhibits HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester, and inhibits the damage of a liver cell and the formation of a fatty liver. Also neohesperid in dihydrochalcone strongly inhibits the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and reduces the concentration of blood sugar.
Abstract translation: 目的：提供一种包含二氢查耳酮中新月皮的药物组合物和功能性食品和饮料，用于治疗和预防高脂血症，动脉硬化，肝脏疾病和高血糖症。 组成：药物组合物含二氢查耳酮中的新皮肤无效量; 和药学上可接受的载体。 功能性食品或饮料包含二氢查耳酮中的新鲜皮肤的0.01-20重量％，优选0.1-5重量％。 新橙皮苷二氢查耳酮降低血清GOT（谷氨酸 - 草酰乙酸转氨酶），GPT（谷氨酸 - 丙酮酸转氨酶）和血液中的脂质的浓度，抑制与生物合成相关的还原酶的HMG CoA（3-羟基-3-甲基戊二酰辅酶） 的胆固醇和ACAT（酰基CoA;胆固醇-O-酰基转移酶），其将胆固醇转化为胆固醇酯，并且抑制肝细胞的损伤和脂肪肝的形成。 二氢查耳酮中的新生皮肤也强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面，并降低血糖浓度。
-
公开(公告)号：KR1020000019716A
公开(公告)日：2000-04-15
申请号：KR1019980037958
申请日：1998-09-15
Applicant: 한국과학기술연구원
IPC: A61K31/70
CPC classification number: A61K31/34 , Y10S514/866
Abstract: PURPOSE: A pharmaceutical composition and a functional food comprising bioflavonoid compounds are provided, for descending blood sugar. CONSTITUTION: The pharmaceutical composition comprises the bioflavonoid compounds represented by the formula 1 in effective amount; and pharmaceutically acceptable carriers. In the formula 1, R¬1 represents OH, rutinosyl or rhaminosyl group, R¬2 represents H, OH or rutinosyl group, R¬3 represents H or OH group, R¬4 represents OH or method group, and X represents a single bond or a double bond. The functional food comprises 0.01-50 wt%, preferably 0.05-10 wt% of the bioflavonoid compounds. The compounds of the formula 1 descends blood sugar, and therefore can be used for treating or preventing hyperglycemia.
Abstract translation: 目的：提供包含生物类黄酮化合物的药物组合物和功能性食品，用于降血糖。 构成：药物组合物包含有效量的式1所示的生物类黄酮化合物; 和药学上可接受的载体。 在式1中，R 1表示OH，芸香酰基或脱氨基糖基，R 2表示H，OH或芸香糖基，R 3表示H或OH基，R 4表示OH或方法基，X表示单 债券或双重债券。 功能性食品包含0.01-50重量％，优选0.05-10重量％的生物类黄酮化合物。 式1的化合物降低血糖，因此可用于治疗或预防高血糖症。
-
-
公开(公告)号：KR1019990076178A
公开(公告)日：1999-10-15
申请号：KR1019980010888
申请日：1998-03-28
Applicant: 한국과학기술연구원
IPC: A61K31/7048 , A61P1/16
Abstract: 본 발명은 헤스페리딘(hesperidin)을 포함하는 간 질환의 예방 및 치료용 조성물에 관한 것으로, 본 발명의 조성물은 의약용 및 식품용 조성물을 포함한다. 헤스페리딘은 동물에게 투여되었을 때 혈청 GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase) 및 γGTP(γ-glutamyl transpeptidase)의 농도를 강하시키므로 본 발명의 조성물은 각종 간 질환의 예방 및 치료제로서 유용하게 사용될 수 있다.
-
Patent Agency Ranking
公开(公告)号：KR1019990034091A
公开(公告)日：1999-05-15
申请号：KR1019970055580
申请日：1997-10-28
Applicant: 한국과학기술연구원
IPC: A61K36/752 , A61P9/00
Abstract: 본 발명은 감귤류 과피의 추출액을 포함하는 아실 코에이: 콜레스테롤-o-아실트랜스퍼레이즈(acyl CoA: cholesterol-o-acyltransferase, ACAT) 활성 저해제 조성물에 관한 것으로, 본 발명의 조성물은 의약용 및 식품용 조성물을 포함한다. 본 발명의 조성물은 동물체내의 ACAT 활성을 저해하여 혈중 저밀도 지단백질(LDL) 콜레스테롤을 감소시키므로 각종 심혈관계 질환의 예방 및 치료제로서 유용하게 사용될 수 있다.
-
7.发明授权
公开(公告)号：KR100125129B1
公开(公告)日：1997-11-28
申请号：KR1019940019984
申请日：1994-08-13
Applicant: 한국과학기술연구원
IPC: C12P1/02
Abstract: The present invention is related to new compounds, GERI-BP001 (C27H33NO5) which is acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor separated from fungus Aspergillus fumigatus FM-F-37 isolated from the earth and its derivatives and to the method for preparation therof. The GERI-BP001 and its derivatives, GERI-BP001-A and GERI-BP001-B are useful for the treatment of hyperlipemia by inhibiting cholesterol trasferase in blood. The GERI-BP001 together its derivatives, GERI-BP001-A and GERI-BP001-B are separated and purified from cultures of Aspergillus sp. strains including Aspergillus fumigatus FM-F-37, GERI-BP001-C can be prepared chemically from GERI-BP001-A by means of nucleophilic substitution reactions.
Abstract translation: 本发明涉及从分离自地球及其衍生物的真菌烟曲霉FM-F-37分离的酰基辅酶A：胆固醇酰基转移酶（ACAT）抑制剂GERI-BP001（C27H33NO5）和制备方法的新化合物 therof。 GERI-BP001及其衍生物GERI-BP001-A和GERI-BP001-B可用于通过抑制血液中的胆固醇trasferase来治疗高脂血症。 将GERI-BP001及其衍生物GERI-BP001-A和GERI-BP001-B从曲霉菌培养物中分离和纯化。 包括烟曲霉FM-F-37，GERI-BP001-C的菌株可以通过亲核取代反应由GERI-BP001-A化学制备。
-
-
公开(公告)号：KR1019960030789A
公开(公告)日：1996-09-17
申请号：KR1019950002058
申请日：1995-02-06
Applicant: 한국과학기술연구원
IPC: A01N63/00
Abstract: 본 발명은 미생물이 이용할 수 있는 생체 고분자를 포함하는 천연 물질, 그로부터 추출된 미생물이 이용할 수 있는 생체 고분자 및 그들의 유도체를 물과 혼합하여 고온에서 겔 상태로 만들고; 상기 겔을 저온으로 냉각시키고; 하나 이상의 길항, 미생물을 상기 겔과 혼합하는 단계들을 포함하는 액상 생체고분자 겔내에 캡슐화된 미생물 농약의 제조 방법 및 그에 의해 제조된 미생물 농약에 관한 것이다.
-
-
-
-
-
-
-
-
Search Results
45
records
(took 0.024 seconds)
